Amsterdam-based Philips designed the platform to speed up cardiac ultrasound analysis with proven AI technology. This aims to reduce the burden on echocardiography labs. It integrated the AI into its EPIQ CVx and Affiniti CVx ultrasound systems.
The FDA-cleared AI applications advance the company’s cardiovascular imaging and diagnosis solutions, according to a news release. Philips says the technology automates measurements and speeds up workflows, increasing productivity.
Philips plans to share data next week at the American Society of Echocardiography (ASE2024). Results demonstrate how its AI can help provide accurate detection of regional wall motion abnormalities (RWMA) on echocardiography.
The company trained its AI on anonymized patient data sets from real-life clinical environments. Its AI features automate ultrasound interpretation, allowing clinicians with varying levels of ultrasound experience to automatically analyze images with increased speed, efficiency and accuracy in real time.
“By harnessing the power of AI into our echocardiography solutions, we empower clinicians with enhanced diagnostic capabilities, to ultimately improve patient care and outcomes in the management of coronary and valvular disease, while enhancing overall efficiency in cardiac practice,” said David Handler, VP and business leader for Global Cardiovascular Ultrasound at Philips. “For patients, this means consistent image interpretation which can lead to fewer re-scans, shorter and more effective interventional procedures, and potentially faster recovery times.”
